STEP 2

Definition

The phase 3 trial of semaglutide 2.4 mg in adults with overweight or obesity AND type 2 diabetes. Davies and colleagues (Lancet 2021) reported -9.6% body weight at 68 weeks on semaglutide 2.4 mg versus -3.4% on placebo and HbA1c reduction of -1.6 percentage points — the pivotal trial supporting Wegovy use in T2D populations alongside Ozempic.

STEP 2 trial deep-dive →

Definition curated by Weight Loss Rankings — sourced from FDA labels and peer-reviewed PubMed literature, never AI-generated summaries.

Related terms in trial

• SURMOUNT-5
• SURMOUNT-2
• SURMOUNT-3
• SURPASS-2
• SUSTAIN-6
• REWIND
• PIONEER 6
• STEP-HFpEF
• EXSCEL
• ELIXA
• AMPLITUDE-O
• HARMONY OUTCOMES
• SCALE Diabetes
• SUMMIT
• SCALE Maintenance

Looking for more depth?

• STEP 2 trial deep-dive
• Browse the full GLP-1 glossary (124 terms across 8 categories)
• Research articles — primary-source deep dives
• Tools and calculators
• Compare GLP-1 telehealth providers